Pamidronate reduces bone loss after allogeneic stem cell transplantation

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 10, 2006, Pages 3835-3843

  Grigg, A P ^a   Shuttleworth, P ^a   Reynolds, J ^b   Schwarer, A P ^c   Szer, J ^a   Bradstock, K ^d   Hui, C ^e   Herrmann, R ^f   Ebeling, P R ^a,g  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

^e ROYAL ADELAIDE HOSPITAL   (Australia)

^f ROYAL PERTH HOSPITAL   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; CYCLOSPORIN; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE DENSITY; BONE DISEASE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FEMUR NECK; HIP; HORMONE BLOOD LEVEL; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 33749580962     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-0684     Document Type: Article

References (43)

1. Ebeling PR 2005 Bone disease after bone marrow transplantation. In: Compston J, Shane E, eds. Bone disease of organ transplantation, Chap 19. Burlington, MA: Elsevier, Academic Press; 339-352
2. Ebeling PR, Thomas DM, Erbas B, Hopper JL, Szer J, Grigg AP 1999 Mechanisms of bone loss in allogeneic and autologous hematopoietic stem cell transplantation. J Bone Miner Res 14:342-350
3. Schulte C, Beelen D, Schaefer U, Mann K 2000 Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos Int 11:344-353
4. Gandhi MK, Lekamwasam S, Inman I, Kaptoge S, Sizer L, Love S, Bearcroft PW, Milligan TP, Price CP, Marcus RE, Compston JE 2003 Significant and persistent loss of bone mineral density in the femoral neck after haematopoietic stem cell transplantation: long-term follow-up of a prospective study. Br J Haematol 121:462-468
5. Weilbaecher KN 2000 Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant 6:165-174
6. Stern JM, Sullivan KM, Ott SM, Seidel K, Fink JC, Longton G, Sherrard DJ 2001 Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study. Biol Blood Marrow Transplant 7:257-264
7. Massenkeil G, Fiene C, Rosen O, Michael R, Reisinger W, Arnold R 2001 Loss of bone mass and vitamin D deficiency after hematopoietic stem cell transplantation: standard prophylactic measures fail to prevent osteoporosis. Leukemia 15:1701-1705
8. Shapiro CL, Manola J, Leboff M 2001 Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311
9. Banfi A, Podesta M, Fazzuoli L, Sertoli MR, Venturini M, Santini G, Cancedda R, Quarto R 2001 High-dose chemotherapy shows a dose-dependent toxicity to bone marrow osteoprogenitors: a mechanism for post-bone marrow transplantation osteopenia. Cancer 92:2419-2428
10. Galotto M, Berisso G, Delfino L, Podesta M, Ottaggio L, Dallorso S, Dufour C, Ferrara GB, Abbondandolo A, Dini G, Bacigalupo A, Cancedda R, Quarto R 1999 Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp Hematol 27:1460-1466
11. Lee WY, Kang MI, Oh ES, Oh KW, Han JH, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The role of cytokines in the changes in bone turnover following bone marrow transplantation. Osteoporos Int 13:62-68
12. Lee WY, Cho SW, Oh ES, Oh KW, Lee JM, Yoon KH, Kang MI, Cha BY, Lee KW, Son HY, Kang SK, Kim CC 2002 The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J Clin Endocrinol Metab 87:329-335
13. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C 2000 Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000
14. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN 2001 Vertebral fracture risk with long-term corticosteroid therapy: prevalence and relation to age, bone density, and corticosteroid use. Arch Intern Med 161:1780-1781
15. Cohen A, Ebeling PR, Sprague S, Shane E, Transplantation osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Chap 56. Washington DC: American Society for Bone and Mineral Research; 302-309
16. Valimaki M, Kinnunen K, Volin L, Tahtela R, Loyttniemi E, Laitinen K, Makela P, Keto P, Ruutu T 1999 A prospective study of bone loss and turnover after allogeneic bone marrow transplantation: effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant 23:355-361
17. Arekat MR, And G, Lemke S, Moses AM 2002 Dramatic improvement of BMD following vitamin D therapy in a bone marrow transplant recipient. J Clin Densitom 5:267-271
18. Kreutz M, Eissner G, Hahn J, Andreesen R, Drobnik W, Holler E 2004 Variations in 1α,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 serum levels during allogeneic bone marrow transplantation. Bone Marrow Transplant 33:871-873
19. Castelo-Branco C, Rovira M, Pons F, Duran M, Sierra J, Vives A, Balasch J, Fortuny A, Vanrell J 1996 The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas 23:307-312
20. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA 1999 Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133-138
21. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste. Marie LG, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382-387
22. Fitton A, McTavish D 1991 Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318
23. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD 1998 Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602
24. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Van Kuijk C 1994 Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503-1514
25. Kananen K, Volin L, Laitinen K, Alfthan H, Ruutu T, Valimaki MJ 2005 Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab 90:3877-3885
26. Ebeling PR 2005 Is defective osteoblast function responsible for bone loss from the proximal femur despite pamidronate therapy? J Clin Endocrinol Metab 90:4414-4416
27. Fan S, Almond MK, Ball E, Evans K, Cunningham J 2000 Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int 57:684-690
28. Shane E, Rodino MA, McMahon DJ, Addesso V, Staron RB, Seibel MJ, Mancini D, Michler RE, Lo SH 1998 Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J Heart Lung Transplant 17:1089-1096
29. Chan SS, Nery LM, McElduff A, Wilmshurst EG, Fulcher GR, Robinson BG, Stiel JN, Gunton JE, Clifton-Bligh PB 2004 Intravenous pamidronate in the treatment and prevention of osteoporosis. Intern Med J 34:162-166
30. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS 2001 Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345:948-955
31. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer Al, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661
32. Kerschan-Schindl K, Mitterbauer M, Fureder W, Kudlacek S, Grampp S, Bieglmayer C, Fialka-Moser V, Pietschmann P, Kalhs P 2004 Bone metabolism in patients more than five years after bone marrow transplantation. Bone Marrow Transplant 34:491-496
33. Tauchmanova L, Selleri C, Esposito M, Di Somma C, Orio F, Jr., Bifulco G, Palomba S, Lombardi G, Rotoli B, Colao A 2003 Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 14:1013-1019
34. Tauchmanova L, Ricci P, Serio B, Lombardi G, Colao A, Rotoli B, Selleri C 2005 Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab 90:627-634
35. D'Souza A, Grigg AP, Szer J, Ebeling PR 2006 Zoledronic acid prevents bone loss after allogeneic stem cell transplantation. Intern Med J 36:600-603
36. Crawford BAL, Kam C, Pavlovic J, Byth K, Handelsman DJ, Angus PW, McCaighan GW 2006 Zoledronic acid prevents bone loss after liver transplantation. Ann Int Med 144:239-248
37. Rosen CJ, Brown S 2003 Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348:1503-1504
38. Marx RE, Sawatari Y, Fortin M, Broumand V 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575
39. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S 2003 Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457-463
40. Evans RA, MacDonald D 1983 Diphosphonates and painful feet. Aust NZ J Med 13:175-176
41. Ali SM, Esteva FJ, Hortobagyi G, Harvey H, Seaman J, Knight R, Costa L, Lipton A 2001 Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434-3437
42. Tauchmanova L, De Rosa G, Serio B, Fazioli F, Mainolfi C, Lombardi G, Colao A, Salvatore M, Rotoli B, Selleri C 2003 Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer 97:2453-2461
43. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D 2004 Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 350:767-776